In a nutshell This study investigated the role of trastuzumab (Herceptin) as part of standard care in patients with human epidermal growth factor receptor-2 positive (HER2+) early breast cancer (BC). The study conclude that trastuzumab was effective in general practice, including patients not often included in clinical trials (such as the...
Read More
In a nutshell This study determined whether certain risk factors predicted outcomes in primary refractory Hodgkin lymphoma. The authors concluded that risk factors such as stage IV disease and cancer activity seen on imaging predicted worse overall outcomes. Some background Refractory disease Hodgkin lymphoma patients are those who are...
Read MoreIn a nutshell This study determined the impact of cancer-related fatigue on Hodgkin-Lymphoma patients and survivors. The authors concluded that fatigue particularly affected social integration. Some background Hodgkin-Lymphoma (HL) patients and survivors can experience persistent cancer-related fatigue. Reports of fatigue occur 2.5 to 3...
Read More
In a nutshell This study determined whether risk-adapted, salvage-chemotherapy response improved survival in patients with relapsed or refractory disease. The authors concluded that treating patients based on their number of risk factors improved outcomes. Some background Some Hodgkin lymphoma patients either do not respond to treatment...
Read MoreIn a nutshell This study determined whether a faster course of salvage chemotherapy reduced tumor volume in patients with relapsed or refractory Hodgkin lymphoma. The authors concluded that shorter intervals between SC cycles was safe and effective. Some background Hodgkin lymphoma is considered to be a highly curable form of...
Read More
In a nutshell This study investigated whether end-of-treatment PET scans could be left out if the mid-treatment scans were negative (no cancer activity). The authors concluded that the end-of-treatment scans were essential, even in patients with negative interim results. Some background Positron emission tomograpy (PET) scans are used to...
Read More
In a nutshell This trial compared the outcomes of ABVD and Stanford-V chemotherapy in patients with stage I or stage II bulky Hodgkin lymphoma. The authors concluded that both treatments were equally effective. Some background Hodgkin Lymphoma is a cancer of the lymph system. Patients with bulky disease have tumors larger than 10 cm....
Read More
In a nutshell This trial examined the need for radiotherapy among early-stage Hodgkin lymphoma patients who responded well to chemotherapy. The authors concluded that in these patients, progression-free survival rates were high overall, but were slightly higher with additional radiation. Some background Hodgkin lymphoma is a cancer...
Read MoreIn a nutshell This trial examined which children with Hodgkin lymphoma benefit from radiation therapy after chemotherapy. The authors concluded that patients with a combination of bulky disease (tumors larger than 6 cm) and anemia (low levels of red blood cells) benefited most. Some background Hodgkin lymphoma is a cancer of the lymph...
Read More
In a nutshell This study assessed whether patients with relapsed- or refractory Hodgkin Lymphoma should be treated with radiation therapy. The authors concluded that radiation therapy was safe and prevented the return of the disease in certain patients. Some background Hodgkin lymphoma is a cancer of the lymph system. It is a...
Read More
In a nutshell This study examined the relationship between the time taken to start adjuvant chemotherapy and survival. The authors determined that a delay in adjuvant chemotherapy was associated with reduced survival. Some background Adjuvant chemotherapy is additional chemotherapy given after surgery. It is routinely used in women who are at risk...
Read More
In a nutshell This study examined the safety and effectiveness of BEACOPP chemotherapy combined with ABVD chemotherapy in patients with early unfavorable Hodgkin lymphoma. This study concluded that the combination of the two chemotherapies was more effective than ABVD alone. The combination increased the rate of negative side effects. Some background...
Read More
